PMID- 36263075
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221021
IS  - 2636-1558 (Electronic)
IS  - 2636-154X (Print)
IS  - 2636-154X (Linking)
VI  - 2
IP  - 1
DP  - 2020 Jan
TI  - Sodium-glucose Co-transporters-2 Inhibitors and Heart Failure: State of the Art 
      Review and Future Potentials.
PG  - 12-22
LID - 10.36628/ijhf.2019.0013 [doi]
AB  - Heart failure (HF) and type 2 diabetes mellitus (T2DM) are progressive chronic 
      diseases that increase the risk of mortality and have worse outcomes when they 
      coexist. There has been a paucity of data on effective therapeutic measures that 
      reduce the risk of HF in patients with T2DM. However, the issuance of the Food 
      and Drug Administration guidance in 2008 generated data on several 
      antihyperglycemic agents that show cardiovascular (CV) benefits beyond glucose 
      lowering. Among them, sodium-glucose co-transporter 2 (SGLT2) inhibitors have 
      emerged as a class of drug with proven robust benefits in modulating HF and 
      kidney diseases in patients with T2DM. In this article, we reviewed the 
      epidemiology, pathophysiology, prognosis, lifestyle management, and therapeutic 
      options, especially SGLT2 inhibitors, for HF and T2DM.
CI  - Copyright (c) 2020. Korean Society of Heart Failure.
FAU - Kato, Eri Toda
AU  - Kato ET
AUID- ORCID: 0000-0001-6484-7743
AD  - Department of Cardiovascular Medicine, Kyoto University Graduate School of 
      Medicine, Kyoto, Japan.
FAU - Kimura, Takeshi
AU  - Kimura T
AD  - Department of Cardiovascular Medicine, Kyoto University Graduate School of 
      Medicine, Kyoto, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200113
PL  - Korea (South)
TA  - Int J Heart Fail
JT  - International journal of heart failure
JID - 101775659
PMC - PMC9536731
OTO - NOTNLM
OT  - Antihyperglycemic agents
OT  - Heart failure
OT  - SGLT2 inhibitors
OT  - Type 2 diabetes
COIS- Conflict of Interest: Kato ET reports personal fees from AstraZeneca, 
      Bristol-Myers Squibb, Daiichi Sankyo, MSD KK, and Tanabe-Mitsubishi Pharma, as 
      well as grant and personal fees from Ono Pharmaceutical. Kimura T reports funds 
      from Boehringer Ingelheim, Astellas Pharma Inc., and funds and grant from Daiichi 
      Sankyo.
EDAT- 2020/01/13 00:00
MHDA- 2020/01/13 00:01
PMCR- 2020/01/13
CRDT- 2022/10/20 02:54
PHST- 2019/11/05 00:00 [received]
PHST- 2019/12/19 00:00 [revised]
PHST- 2019/12/31 00:00 [accepted]
PHST- 2022/10/20 02:54 [entrez]
PHST- 2020/01/13 00:00 [pubmed]
PHST- 2020/01/13 00:01 [medline]
PHST- 2020/01/13 00:00 [pmc-release]
AID - 10.36628/ijhf.2019.0013 [doi]
PST - epublish
SO  - Int J Heart Fail. 2020 Jan 13;2(1):12-22. doi: 10.36628/ijhf.2019.0013. 
      eCollection 2020 Jan.